Please use this identifier to cite or link to this item:
|Title:||Epidermal growth factor inhibitors in first-line for metastatic colorectal cancer with ras wild-type: a perspective based on pharmacological costs||Authors:||Giuliani, Jacopo
|Keywords:||ESMO-MCBS;Metastatic colorectal cancer;epidermal growth factor receptor inhibitors;first-line therapy;randomized phase III trials||Keywords Plus:||PHASE-III TRIAL;CETUXIMAB;CHEMOTHERAPY;BEVACIZUMAB;FLUOROURACIL;PANITUMUMAB;LEUCOVORIN||Mesh headings:||Antineoplastic Agents;Colorectal Neoplasms;ErbB Receptors||Secondary Mesh headings:||Antineoplastic Combined Chemotherapy Protocols;Clinical Trials, Phase III as Topic;Disease-Free Survival;Drug Costs;Genes, ras;Humans;Neoplasm Metastasis;Protein Kinase Inhibitors;Randomized Controlled Trials as Topic||Issue Date:||Jun-2017||Publisher:||TAYLOR & FRANCIS LTD||Journal:||Expert review of pharmacoeconomics & outcomes research||Abstract:||
In light of the relevant expenses of pharmacological interventions it might be interesting to make a balance between the cost of the new drugs administered, such as EGFRIs (cetuximab and panitunumab) and the added value represented by the improvement of the clinical parameters of interest such as progression free survival (PFS). Areas covered: The analysis was conducted to assess the effect of front-line chemotherapy on the PFS, separately, on each arm of the evaluated trials. Only phase III randomized controlled trials (RCTs) were considered. We calculated the pharmacological costs necessary to get the benefit in PFS, for each trial. We have subsequently applied the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) to the above phase III RCTs. Our analysis evaluated 9 phase III RCTs, including 7199 patients. ESMO-MCBS reached high scores (grade 4) for the CRYSTAL and PRIME trials. The combination of FOLFOX and panitunumab is associated with low difference per month-PFS gained (15 821.9 €) instead of FOLFIRI plus cetuximab (21 854.6 €) in KRAS wild-type patients. Expert commentary: Our data demonstrate a huge difference in cost per month of PFS gained in modern front-line treatments in mCRC with RAS wild-type.
|Appears in Collections:||Articles|
Show full item record
checked on Jul 15, 2021
checked on Aug 31, 2020
WEB OF SCIENCETM
checked on Nov 24, 2021
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.